Table 1.
Patient demographic and clinical characteristics
| Full population (excluding those with regular visits) (n = 20,041) | Regular visits sub-cohort (n = 9812) | |
|---|---|---|
| Age, mean years (SD) | 57.9 (13.4) | 59.3 (13.5) |
| Sex, n female (%) | 15,193 (76.3) | 7360 (75.8) |
| Duration of RA, mean years (SD) | 9.1 (9.7) | 8.7 (9.7) |
| Disabled, n (%) | 2439 (12.3) | 1072 (11.1) |
| Patient paina, mean score (SD) | 34.6 (27.7) | 33.6 (27.8) |
| TJC28, mean n (SD) | 4.6 (6.2) | 4.1 (5.8) |
| SJC28, mean n (SD) | 4.5 (5.6) | 3.6 (5.0) |
| PtGA, mean score (SD) | 32.0 (26.7) | 30.9 (26.6) |
| PGA, mean score (SD) | 25.7 (21.9) | 23.5 (21.5) |
| CDAI, mean score (SD) | 14.8 (13.3) | 13.0 (12.6) |
| CDAI category, n (%) | ||
| Low (score >2.8 to ≤10) | 9435 (47.1) | 5269 (53.7) |
| Moderate (score >10 to ≤22) | 5674 (28.3) | 2634 (26.8) |
| Severe (score >22) | 4929 (24.6) | 1909 (19.5) |
| History of biologic DMARD use, n (%) | 9411 (47.0) | 4485 (45.7) |
SD standard deviation, RA rheumatoid arthritis, TJC28 tender joint count based on 28 joints, SJC28 swollen joint count based on 28 joints, PtGA patient global assessment, PGA physician global assessment, CDAI Clinical Disease Activity Index, DMARD disease-modifying antirheumatic drug
aPatient pain was rated on a visual analog scale of 0–100